Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MYO 
Myomo Inc (MYO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: MYO (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.3
1 Year Target Price $5.3
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 62.18% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 39.69M USD | Price to earnings Ratio - | 1Y Target Price 5.3 |
Price to earnings Ratio - | 1Y Target Price 5.3 | ||
Volume (30-day avg) 5 | Beta 1.4 | 52 Weeks Range 0.93 - 7.17 | Updated Date 08/30/2025 |
52 Weeks Range 0.93 - 7.17 | Updated Date 08/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.1 | Actual -0.11 |
Profitability
Profit Margin -22.87% | Operating Margin (TTM) -47.56% |
Management Effectiveness
Return on Assets (TTM) -21.22% | Return on Equity (TTM) -68.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 36639643 | Price to Sales(TTM) 0.97 |
Enterprise Value 36639643 | Price to Sales(TTM) 0.97 | ||
Enterprise Value to Revenue 0.9 | Enterprise Value to EBITDA -0.82 | Shares Outstanding 37801100 | Shares Floating 29338544 |
Shares Outstanding 37801100 | Shares Floating 29338544 | ||
Percent Insiders 7.02 | Percent Institutions 66.28 |
Upturn AI SWOT
Myomo Inc
Company Overview
History and Background
Myomo, Inc. was founded in 2004 as Myomo, LLC and incorporated in Delaware in 2013. It focuses on developing and commercializing myoelectric orthoses for individuals with upper extremity paralysis.
Core Business Areas
- MyoPro Medical Device: Designs, develops and commercializes the MyoPro, a myoelectric upper limb orthosis intended to restore function in paralyzed or weakened arms and hands.
Leadership and Structure
Paul R. Gudonis is the Chief Executive Officer. The company operates with a functional organizational structure.
Top Products and Market Share
Key Offerings
- MyoPro: The MyoPro is a powered brace that helps individuals with neuromuscular conditions regain function in their arms and hands. Market share data is difficult to ascertain precisely due to the niche market. Competitors include conventional therapies and other assistive devices, but the MyoPro is a unique device. Revenue from MyoPro sales is the primary source of revenue for Myomo.
Market Dynamics
Industry Overview
The industry involves medical devices for rehabilitation and assistive technology for individuals with upper extremity paralysis. The market is driven by an aging population, increasing prevalence of neurological disorders, and technological advancements.
Positioning
Myomo is positioned as a provider of innovative myoelectric orthoses, differentiating itself through its proprietary technology and focus on restoring function. They have a competitive advantage due to the MyoPro device being one of the only devices in the market.
Total Addressable Market (TAM)
The TAM for upper extremity assistive devices is estimated to be in the billions. Myomo is positioned to capture a portion of this market through increased awareness and adoption of its MyoPro device.
Upturn SWOT Analysis
Strengths
- Proprietary myoelectric technology
- Focus on restoring function
- Established reimbursement pathways
- FDA-cleared product
Weaknesses
- Limited financial resources
- Reliance on a single product
- Limited brand recognition
- Small sales force
Opportunities
- Expanding market for assistive devices
- Increasing awareness of myoelectric technology
- Partnerships with rehabilitation centers
- International expansion
Threats
- Competition from established medical device companies
- Reimbursement challenges
- Technological obsolescence
- Economic downturn
Competitors and Market Share
Key Competitors
- EKSO
- REWALK
Competitive Landscape
Myomo's advantages include its proprietary technology and focus on restoring function. Disadvantages include limited financial resources and brand recognition.
Growth Trajectory and Initiatives
Historical Growth: Myomo's historical growth has been driven by increased sales of the MyoPro device.
Future Projections: Analyst estimates vary, but project continued growth driven by market expansion and increased adoption of myoelectric technology.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts, pursuing strategic partnerships, and developing new product features.
Summary
Myomo is a small medical device company with a unique myoelectric orthosis. While their technology holds promise and is an advantage, they are limited by the small size of the company, their financials and ability to make a large impact on the market. They need to continue to find ways to increase revenue and sales, but keep costs at a minimum. Competition is fierce and there is always the threat of obsolescence, so they need to find ways to continually innovate and grow.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Myomo Inc. SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Data is based on available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Myomo Inc
Exchange NYSE MKT | Headquaters Burlington, MA, United States | ||
IPO Launch date 2017-06-12 | President, CEO & Chairman Mr. Paul R. Gudonis | ||
Sector Healthcare | Industry Medical Devices | Full time employees 184 | Website https://myomo.com |
Full time employees 184 | Website https://myomo.com | ||
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.